Company Overview
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Why Investors Should Care
Generates a return on equity of 50.6%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 23.4%.
Revenue has grown at a 113.3% CAGR over the past five years.
Trades at a P/E of 6.7, below the sector median of 24.8.
Maintains a net profit margin of 47.6%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $72.76M (+161.1% YoY); net profit $35.34M.
- Trailing 12 Months Year-on-year growth — revenue +107.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 113.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 113.28% |
| 1 Year: | 107.00% |
Stock Price Performance
| 1 Year: | +72.97% |
| 6 Months: | +19.07% |
| 3 Months: | +25.49% |
| 1 Month: | +6.22% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.72 · Neutral
P/E of 6.74 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 50.6%.
- Healthy ROCE of 23.4%.
- Excellent profit margin of 47.6%.
- Compounding revenue at 113.3% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CGEN Compugen Ltd. PHARMA | 2.56 | 6.74 | $242.49M | 0.00% | 23.38% | 50.64% | 113.28% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 2.28M | 1.26M | 1.89M | 67.33M | 2.18M |
| Cost of Revenue | - | 2.40M | 1.67M | 1.65M | 3.54M | 1.82M |
| Gross Profit | - | -116.00K | -408.00K | 241.00K | 63.80M | 352.00K |
| Operating Expenses | - | 8.28M | 8.02M | 8.13M | 7.75M | 9.37M |
| Operating Income | - | -8.39M | -8.43M | -7.89M | 56.04M | -9.02M |
| EBITDA | - | -8.39M | -8.43M | -7.89M | 56.04M | -9.02M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -7.15M | -7.36M | -6.94M | 56.84M | -7.66M |
| Tax Provision | - | 31.00K | -17.00K | 40.00K | 0 | 5.00K |
| Net Income | - | -7.18M | -7.34M | -6.98M | 56.84M | -7.67M |
| Diluted EPS | - | -0.08 | -0.08 | -0.07 | 0.60 | -0.08 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 7.50M | 33.46M | 27.86M | 72.76M |
| Cost of Revenue | - | 975.00K | 2.00M | 7.93M | 9.25M |
| Gross Profit | - | 6.53M | 31.45M | 19.93M | 63.51M |
| Operating Expenses | - | 41.90M | 44.45M | 34.83M | 32.19M |
| Operating Income | - | -35.37M | -12.99M | -14.89M | 31.33M |
| EBITDA | - | -34.89M | -12.52M | -14.40M | 31.80M |
| Interest Expense | 25.00K | 27.00K | - | - | - |
| Pretax Income | - | -33.64M | -9.78M | -9.71M | 35.40M |
| Tax Provision | - | 58.00K | 8.97M | 4.52M | 54.00K |
| Net Income | - | -33.69M | -18.75M | -14.23M | 35.34M |
| Diluted EPS | - | -0.39 | -0.21 | -0.16 | 0.38 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 94.18M | 121.33M | 115.00M | 156.57M |
| Current Assets | - | 86.12M | 114.58M | 106.00M | 148.02M |
| Cash & Equivalents | - | 11.06M | 13.89M | 18.23M | 90.60M |
| Inventory | - | - | - | - | - |
| Receivables | 0 | 0 | 61.00M | 0 | - |
| Total Liabilities | - | 16.50M | 55.77M | 60.08M | 53.84M |
| Current Liabilities | - | 11.92M | 26.27M | 20.16M | 22.57M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 1.93M | 1.35M | 2.91M | 2.96M |
| Total Equity | - | 77.68M | 65.56M | 54.91M | 102.73M |
| Shares Outstanding | - | 86.62M | 89.24M | 89.54M | 94.55M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -34.11M | -35.89M | 49.60M | 31.63M |
| Investing Cash Flow | - | 37.06M | 35.51M | -46.25M | 30.00M |
| Financing Cash Flow | - | 353.00K | 3.08M | 554.00K | 10.60M |
| Capital Expenditure | - | -487.00K | -172.00K | -118.00K | -306.00K |
| Free Cash Flow | - | -34.60M | -36.06M | 49.49M | 31.33M |
| Net Change in Cash | - | 3.30M | 2.71M | 3.91M | 72.23M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 87.0% | 94.0% | 71.5% | 87.3% |
| Operating Margin % | - | -471.7% | -38.8% | -53.4% | 43.1% |
| Net Margin % | - | -449.3% | -56.1% | -51.1% | 48.6% |
| ROE % | - | -43.4% | -28.6% | -25.9% | 34.4% |
| ROCE % | - | -43.0% | -13.7% | -15.7% | 23.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | SilverArc Capital Management, LLC | 3.40% | 3.18M | $7.93M |
| 2 | Renaissance Technologies, LLC | 2.01% | 1.88M | $4.67M |
| 3 | Morgan Stanley | 1.12% | 1.05M | $2.62M |
| 4 | Nomura Asset Management International Inc | 1.09% | 1.02M | $2.54M |
| 5 | Taylor Frigon Capital Management LLC | 0.90% | 842.18K | $2.10M |
| 6 | ARK Investment Management, LLC | 0.84% | 786.54K | $1.96M |
| 7 | Altshuler Shaham Ltd | 0.56% | 521.62K | $1.30M |
| 8 | Two Sigma Investments, LP | 0.55% | 512.42K | $1.28M |
| 9 | State Street Corporation | 0.44% | 415.67K | $1.04M |
| 10 | Atom Investors LP | 0.32% | 303.53K | $755.78K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CGEN
A cancer treatment company will speak live Sept. 14. Compugen’s talk will be webcast. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPdF9rQW5zakVfRkFzQ08zdXFzZHg1V1hvQl9JY0s2cU9GNkJmVHNIZEQwR1BTXzV2UzJ1RlhLMlFtWS1ZNnZSMU9VU1oxcVB5Y0p5cUZ0Q19VM25TdTkxdmRBS2tkT0J4SVFPM1hIcnQwZW90aElSakhiamd3dzdBZUlQd1c3bmlad2R5Rk…
Compugen (CGEN) Stock Faces Mixed Analyst Target Changes After Cautious Valuation Revisions - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOX1RVa0RQbFFTQjVxeTgwR1hTaWNMV1c1d1BLYnhQSE5pMlNJSzF2MkplbFRLejhzUVRUSkxIZkR6MGdPXy15enpTbW9qclZHZEtFWWlSbFV5NEV0dWxreW5qLU9JdXU0S2dfajhZY1lENDJndWRuNDkycGtNZnRDZmV0N2tOV3UzcWxDM2…
Compugen (CGEN) Stock Holds Steady As Cash Runway Extends To 2029 - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxNZ0d2QUlWYW0ycHpRQ3pXV3hSdGkwMGZZLW5pdnE4RExVcklTXzYtc3dCVm1YQ2F3VTE0SU10ejk5eWp2QnZrdzhxT1VxX3AwRGV0Zkk4cGRXbzlDNkhsc1NudTBlTy1sdk5LNXZ0ajNYTUYzaHRkZmJZdTN4NXRrRE9xSTJaWmN0RENURV…
COMPUGEN ($CGEN) Releases Q2 2026 Earnings | CGEN Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxOdUtYVVNaaVJkek9wNUVfOGR1by1BWFNjcFBVOGk2d3p6QmFiWWRFc0ZteTQ2U2ZpNkJDdWNybHdLeEgtMXFUbXFvWlFCY2h0MXFTUmVRMVItUXQwYVpHendlR0xCZXRNaUVsQ0ZtSU9PV0t6NDgyS0V0N3lLZWxqODlCcTRxVmJT?oc=5"…
CGEN - Compugen Ltd Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBtTkU0ajNYYWNYQ2Z1U0dNbFpXRlpLa2sxYl9xcm8yVHZXQ3FDVExVRDR0cW5tMDBYd1VUdXZTYnhXZEJTMEE?oc=5" target="_blank">CGEN - Compugen Ltd Stock Price and Quote</a> <font color="#6…
CGEN Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1hQlpzLWZscWZ2ZlZwUlZKUERrV093SXBKSFF2eF9IaTVQRDQ3dEY1WnpqaHRsRU9mYTVrUURMMThFN1NSNE5GSDlVYkRvQXBhcmM3UEhoVFVwVThNcTQ4OW5pMEpPanlQa0pQQ0Mwd0lHMG9ITDNGSnp3?oc=5" target="_blank">CGE…
CGEN — Frequently Asked Questions
What is the current share price of Compugen Ltd. (CGEN)?
As of 2026-09-19 21:16 PDT, Compugen Ltd. (CGEN) trades at $2.56 on NasdaqCM. Its 52-week range is $1.33 to $3.10.
What is the market capitalisation of CGEN?
Compugen Ltd. (CGEN) has a market capitalisation of $242.49M on NasdaqCM.
What is the P/E ratio of CGEN?
CGEN trades at a trailing price-to-earnings (P/E) ratio of 6.74. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.65.
What is the return on equity (ROE) of CGEN?
CGEN has a return on equity (ROE) of 50.64%. Its return on capital employed (ROCE) is 23.38%.
Is CGEN a good stock to buy?
This page provides a data-driven analysis of Compugen Ltd. (CGEN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.